Isaac Dietrich, the CEO of MassRoots Inc (OTCMKTS:MSRT) said that the MyDx analyzer has received strong grassroots support which validates there is significant interest from cannabis clients to learn more about the products and strains they purchase. The MyDx device will enable regular cannabis consumers to more properly medicate and consume it in a responsible and safe manner. The company looks forward to share the message with its half million users, and progress with the aim of enhancing the quality of patients’ lives.
The expert view
Daniel Yazbeck, the MyDx founder, said that the device will assist customer trust and verify what they put into their bodies and minds. Their sensor and application, named as CannaDx, analyzes and discloses the broader Terpene and CBD content of Cannabis flower samples. Also, it questions the users about how they feel and did it work? The more the assessment, the more intelligent personalized recommendation engine of customer will become in the MyDx App. As a result, the customers can track and find the strain profiles that work best for them.
The profile
MyDx is a technology and science company based in San Diego, whose mission is to empower customers to live a healthier life by disclosing the purity of what they drink, eat and inhale and in real time. It has developed MyDx device, a portable analyzer that offers real-time chemical analysis and easily fits in the palm of customers. MyDx leverages more than a decade of verified electronic nose technology to assess chemicals of interest and it includes four sensors being formulated in its laboratory that are compatible with the MyDx Analyzer.
In last trading session, the stock price of MassRoots Inc (OTCMKTS:MSRT) jumped more than 16% to close the trading session at $1.68. The gains came at a share volume of 280,391 compared to monthly average share volume of 52,071.
